CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Agenus Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Agenus Inc
3 Forbes Rd
Phone: (781) 674-4410p:781 674-4410 LEXINGTON, MA  02421-7305  United States Ticker: AGENAGEN
Business Summary
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202512/31/2024YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer, Co-Founder, Interim Chief Financial Officer Princip Garo H.Armen 72 1/8/2026 1/1/1994
Vice President - Finance Christine M.Klaskin 59 12/1/2016 10/1/2006
Chief Development Officer RichardGoldberg 5/12/2025 5/12/2025
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
AGENUS UK 315 MILTON ROAD CAMBRIDGE
AGENTUS THERAPEUTICS LTD MILTON ROAD CAMBRIDGE
4-Antibody AG Schwarzwaldallee 215 CH-4002 Basel Switzerland
3 additional Subsidiary records available in full report.

Business Names
Business Name
4-Antibody AG
AGEN
AgenTus Therapeutics Limited
9 additional Business Names available in full report.

General Information
Number of Employees: 316 (As of 2/28/2025)
Outstanding Shares: 36,141,682 (As of 1/15/2026)
Shareholders: 360
Stock Exchange: NASD
Federal Tax Id: 061562417
Fax Number: (781) 674-4200
Email Address: ir@antigenics.com


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, February 3, 2026